20 Jun Fewer Re-infarctions With hs Troponin To Assess Heart Attacks

MedicalResearch.com Interview with:

Dr. Holzmann

Martin J Holzmann MD, PhD
Functional Area of Emergency Medicine
Department of Internal Medicine,
Solna, Karolinska Institutet
Stockholm, Sweden

MedicalResearch.com: What is the background for this study? What are the main findings?

Response: We wanted to investigate how the introduction of the new high-sensitivity cardiac troponin T (hs-cTnT) assay affected incidence of myocardial infarction (MI) use of coronary angiography, cardiac revascularizations, and prognosis in patients with myocardial infarction.

We found that the incidence of MI increased by approximately 5%, with no change in mortality, but with an 11% reduced risk of reinfarctions, and a small increase in coronary angiographies, and cardiac revascularizations by 16%, and 13%, respectively. 

MedicalResearch.com: What should readers take away from your report?

Response: In the US there has been concerns expressed that there would be a massive increase in diagnosed myocardial infarctions, and in addition an large increase in resource utilization. However, our study shows not only that the effects on  myocardial infarction incidence and the use of resources is marginal, but more importantly that the prognosis in patients with  improved with a reduction of reinfarctions. I should not interpret our results for others, but I believe that the results should be reassuring for American hospitals which are thinking of introducing the high-sensitivity troponin assays at this very moment.

MedicalResearch.com: What recommendations do you have for future research as a result of this work?

Response: Obviously the effect seen was in the Swedish setting. The consequences of the introduction of the high-sensitivity assays may be different in the US. Therefore, I think the effects should effects should be evaluated in the american setting as well after the new assays have been used for a while.

Disclosures: I received honoraria from Actelion, Idorsia and Pfizer.

Citation:

Journal of the American College of Cardiology
Volume 71, Issue 23, June 2018
DOI: 10.1016/j.jacc.2018.03.515
High-Sensitivity Troponins and Outcomes After Myocardial Infarction
Maria Odqvist, Per-Ola Andersson, Hans Tygesen, Kai M. Eggers and Martin J. Holzmann 

[wysija_form id=”3″]

The information on MedicalResearch.com is provided for educational purposes only, and is in no way intended to diagnose, cure, or treat any medical or other condition. Always seek the advice of your physician or other qualified health and ask your doctor any questions you may have regarding a medical condition. In addition to all other limitations and disclaimers in this agreement, service provider and its third party providers disclaim any liability or loss in connection with the content provided on this website.

Last Updated on June 21, 2018 by Marie Benz MD FAAD